A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

Trial Profile

A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Liprotamase (Primary)
  • Indications Cystic fibrosis; Exocrine pancreatic insufficiency
  • Focus Registrational; Therapeutic Use
  • Acronyms RESULT
  • Sponsors Anthera Pharmaceuticals
  • Most Recent Events

    • 09 Nov 2017 Status changed from recruiting to active, no longer recruiting, according to an Anthera Pharmaceuticals media release.
    • 06 Nov 2017 According to an Anthera Pharmaceuticals media release, interim futility analysis is expected in December 2017, followed by top line data in Q1 2018.
    • 07 Sep 2017 According to an Anthera Pharmaceuticals media release, more than 50% of the anticipated patients needed to complete enrollment have entered screening for the RESULT trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top